Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

The article compares two emerging biotech stocks: Intellia Therapeutics, which focuses on CRISPR gene-editing technology with promising Phase III trial data but significant losses and clinical risks, and Omeros, which recently achieved FDA approval for Yartemlea and posted its first commercial revenue of $9.89 million. While Intellia offers higher upside potential, Omeros is deemed the safer choice due to its transition to profitability, strong initial sales, and healthier balance sheet, despite trading at a premium valuation.